#South Korea #Rznomics #RZ-001 #Glioblastoma #Seongnam

Rznomics' Breakthrough in Glioblastoma Treatment

At the Asian Society for Neuro-Oncology Annual Meeting (ASNO 2026) held in Kanazawa, Japan, Rznomics Inc. showcased significant interim data for their novel RNA therapy, RZ-001, designed to treat recurrent glioblastoma (rGBM). The findings were shared by Dr. Chae-Yong Kim, a respected professor in the neurosurgery field at Seoul National University Bundang Hospital.

The Clinical Trial Overview

This Phase 1/2a clinical trial features RZ-001, also known as Taspitimagene advec, which employs a unique approach utilizing RNA editing technology. Specifically, it leverages a proprietary trans-splicing ribozyme platform to target tumor cells, thereby triggering cancer cell death directly within these malignant masses. In this ongoing clinical trial, Rznomics has screened 20 patients, of which 10 have been officially enrolled and are undergoing treatment.

The interim analysis derived from these patients has made remarkable observations. Notably, the data indicated no new treatment-related safety concerns arose during the trial, nor were there any incidents of dose-limiting toxicity (DLT). The most common adverse events reported were either associated with underlying health conditions or deemed disease-related, which is typical among patients diagnosed with glioblastoma. Additionally, several patients demonstrated encouraging signs of prolonged inhibition of tumor recurrence and maintained disease control for over six months.

Significance of the Findings

Recurrent glioblastoma is notorious for its aggressive nature and the frequent recurrence of tumors, which severely diminishes patient prognosis even with standard therapies. Current treatment options, notably those classified under conventional immuno-oncology, often fail to yield meaningful results. Therefore, RZ-001 addresses a significant component of unmet medical requirements by introducing a potential new mechanism of action for treating this challenging condition.

Dr. Kim commented, "The data we secured thus far illustrates a tolerable safety profile for RZ-001 alongside some compelling preliminary evidence of its clinical efficacy. Considering the typical recurrence rate of rGBM, which is usually between two to four months post-treatment, the data showing patients extending beyond nine months without recurrence is genuinely promising. We eagerly anticipate defining its comprehensive clinical value through the enrollment of more patients and obtaining long-term observations."

Future Development

Beyond glioblastoma, RZ-001 is also being researched for its potential application in hepatocellular carcinoma (HCC). The HCC phase recently hit a significant milestone, achieving Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA, further underscoring the promising potential of Rznomics’ innovative therapies.

About Rznomics

Established in South Korea, Rznomics Inc. is a clinical-stage biopharmaceutical firm focusing on RNA-based gene therapies. Its pioneering trans-splicing ribozyme platform facilitates accurate RNA editing and possesses broad applicability across numerous medical indications. In May 2025, Rznomics entered a collaborative research and licensing agreement with the global pharmaceutical giant Eli Lilly, with the company going public on the KOSDAQ market in December 2025 under the ticker KOSDAQ 476830.

For more insights on Rznomics and their cutting-edge developments, please visit their official website: www.rznomics.com.